Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women

Zaki, Moushira Erfan; Kamal, Sanaa; Kholousi, Shams; El-Bassyouni, Hala T.; Yousef, Walaa; Abdallah, Hanaa Reyad; Mohamed, Ramy; Basha, Walaa A.

doi:10.17179/excli2017-275

Cited by 8 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This discrepant finding with the literature is most likely due to the low sample size of our cohort ( n = 24) and in particular, our OB group ( n = 7). In addition, individuals in our OB group were mildly obese (class I), whereas previous investigations, including our own, which have demonstrated lower circulating sRAGE isoforms in individuals with obesity have studied individuals that would be characterized as having class II or III obesity based on their BMI ( 10 , 42 , 65 , 82 , 83 ). In addition, the participants in the current study may lack aspects of the obesogenic milieu that drive these relationships.…”

Section: Discussionmentioning

confidence: 99%

Soluble RAGE and skeletal muscle tissue RAGE expression profiles in lean and obese young adults across differential aerobic exercise intensities

Miranda,

Mey,

Blackburn

et al. 2023

Journal of Applied Physiology

View full text Add to dashboard Cite

Nearly 40% of Americans have obesity and are at increased risk for developing type 2 diabetes. Skeletal muscle is responsible for >80% of insulin-stimulated glucose uptake which is attenuated by the inflammatory milieu of obesity and augmented by exercise. The Receptor for Advanced Glycation Endproducts (RAGE) is an inflammatory receptor directly linking metabolic dysfunction with inflammation. Circulating soluble isoforms of RAGE (sRAGE) formed either by proteolytic cleavage (cRAGE) or alternative splicing (esRAGE) act as decoys for RAGE ligands thereby counteracting RAGE-mediated inflammation. PURPOSE We aimed to determine if RAGE expression or alternative splicing of RAGE is altered by obesity in muscle, and whether acute aerobic exercise (AE) modifies RAGE and sRAGE. METHODS Young (20-34y) participants without (n=17; BMI: 22.6±2.6 kg/m2) and with obesity (n=7; BMI: 32.8±2.9 kg/m2) performed acute aerobic exercise (AE) at 40, 65 or 80% of VO2Max (mL/kg/min) on separate visits. Blood was taken before and 30 minutes after each exercise bout. Muscle biopsy samples were taken before, 30 minutes, and 3 hours after the 85% VO2Max exercise bout. RESULTS Individuals with obesity had higher total RAGE and esRAGE mRNA and RAGE protein (p<0.0001). In addition, RAGE and esRAGE transcripts correlated to transcripts of the NF-κB subunit P65 (p<0.05). There was no effect of exercise on total RAGE or esRAGE transcripts, or RAGE protein (p>0.05) and AE tended to decrease circulating sRAGE. CONCLUSIONS RAGE expression is exacerbated in skeletal muscle with obesity, which may contribute to the development of skeletal muscle metabolic dysfunction such as insulin resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Soluble RAGE and skeletal muscle tissue RAGE expression profiles in lean and obese young adults across differential aerobic exercise intensities

Miranda,

Mey,

Blackburn

et al. 2023

Journal of Applied Physiology

View full text Add to dashboard Cite

show abstract

“…Obesity was associated with decreased plasma levels of sRAGE leading to atherosclerosis risk [117,[134][135][136][137][138][139][140][141][142]. The sAGE comprised of the ligand-binding site acts as a decoy receptor that inhibits the attachment of AGEs to RAGE [143].…”

Section: Dietary Ages Influence On Vascular Functionmentioning

confidence: 99%

Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies

Kim

2023

Nutrients

View full text Add to dashboard Cite

Cardiometabolic disorders are characterised by a cluster of interactive risk determinants such as increases in blood glucose, lipids and body weight, as well as elevated inflammation and oxidative stress and gut microbiome changes. These disorders are associated with onset of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). T2DM is strongly associated with CVD. Dietary advanced glycation end products (dAGEs) attributable from modern diets high in sugar and/or fat, highly processed foods and high heat-treated foods can contribute to metabolic etiologies of cardiometabolic disorders. This mini review aims to determine whether blood dAGEs levels and tissue dAGEs levels are determinants of the prevalence of cardiometabolic disorders through recent human studies. ELISA (enzyme-linked immunosorbent assay), high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) for blood dAGEs measurement and skin auto fluorescence (SAF) for skin AGEs measurement can be used. Recent human studies support that a diet high in AGEs can negatively influence glucose control, body weight, blood lipid levels and vascular health through the elevated oxidative stress, inflammation, blood pressure and endothelial dysfunction compared with a diet low in AGEs. Limited human studies suggested a diet high in AGEs could negatively alter gut microbiota. SAF could be considered as one of the predictors affecting risks for cardiometabolic disorders. More intervention studies are needed to determine how dAGEs are associated with the prevalence of cardiometabolic disorders through gut microbiota changes. Further human studies are conducted to find the association between CVD events, CVD mortality and total mortality through SAF measurement, and a consensus on whether tissue dAGEs act as a predictor of CVD is required.

show abstract

“…Because of its unique structure and existing form, RAGE can bind to various ligands, such as S100, calcium/grain, high-mobility group protein 1 (HMGB1), and amyloid β-protein (Aβ) [ 2 ]. Soluble receptor for advanced glycation end products (sRAGE) does not have a signal transmission function due to its lack of transmembrane and intracellular segments [ 3 ]. sRAGE can competitively bind to RAGE ligands, thus antagonizing the pathological effects mediated by RAGE [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases

et al. 2022

View full text Add to dashboard Cite

As a critical molecule in the onset and sustainment of inflammatory response, the receptor for advanced glycation end products (RAGE) has a variety of ligands, such as advanced glycation end products (AGEs), S100/calcium granule protein, and high-mobility group protein 1 (HMGB1). Recently, an increasing number studies have shown that RAGE ligand binding can initiate the intracellular signal cascade, affect intracellular signal transduction, stimulate the release of cytokines, and play a vital role in the occurrence and development of immune-related diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and Alzheimer’s disease. In addition, other RAGE signaling pathways can play crucial roles in life activities, such as inflammation, apoptosis, autophagy, and endoplasmic reticulum stress. Therefore, the strategy of targeted intervention in the RAGE signaling pathway may have significant therapeutic potential, attracting increasing attention. In this paper, through the systematic induction and analysis of RAGE-related signaling pathways and their regulatory mechanisms in immune-related diseases, we provide theoretical clues for the follow-up targeted intervention of RAGE-mediated diseases.

show abstract

Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women

Cited by 8 publications

References 31 publications

Soluble RAGE and skeletal muscle tissue RAGE expression profiles in lean and obese young adults across differential aerobic exercise intensities

Soluble RAGE and skeletal muscle tissue RAGE expression profiles in lean and obese young adults across differential aerobic exercise intensities

Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies

Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases

Contact Info

Product

Resources

About